Northwest Biotherapeutics’ lead candidate, called DCVax-L, is a lysate-loaded dendritic cell vaccine intended for the treatment of glioblastoma multiforme (GBM), the most lethal form of primary brain cancer.
The company’s DCVax technology platform uses activated dendritic cells and is designed to target the full set of biomarkers on a patient’s cancer, making it more difficult for tumors to develop “escape variants”, in which they manage to evade the effects of anti-cancer drugs.
In order to make DCVax for a patient, the patient’s immune cells are obtained through a blood draw. These immune cells are precursors of dendritic cells, called “monocytes.” For DCVax-L, the monocytes are differentiated into dendritic cells and matured, activated, and loaded with antigens from the patient’s own tumor tissue. The dendritic cells are then isolated with very high purity and comprise the DCVax-L personalized vaccine.
In November 2022, Northwest Biotherapeutics reported positive topline results from its phase 3 trial of DCVax-L that showed both median and long tail survival were increased in both newly diagnosed and recurrent glioblastoma. At the time of these results, the company said that it believed this was the first time in nearly 20 years that a phase 3 trial of a systemic treatment had shown such survival extension in newly diagnosed glioblastoma, and the first time in nearly 30 years that a phase 3 trial of any type of treatment had shown such survival extension in recurrent glioblastoma.
Despite the outcome of the phase 3 study, DCVax-L has still not received regulatory approval. In December 2023, a full year after the results were released, the company finally announced that it had submitted a marketing authorization application to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for DCVax-L for glioblastoma brain cancer.
But, still, another year later, and the company is still awaiting the outcome of its approval application. Reports suggest that the company is still working closely with consultants on matters related to the review, including preparing for upcoming inspections by the MHRA in the U.S. and the U.K. The company is also reportedly struggling for cash and is currently funding itself through a shoestring effort. In December 2024, it announced a $5 million convertible note financing and standby facility for up to $50 million in additional financing.
Nevertheless, the potential of DCVax-L remains a focal point for investors. And, considering the talks between the company and the MHRA are still ongoing, the candidate could soon receive approval, especially given its positive phase 3 results, as well as the fact that there is a significant need for more treatment options for glioblastoma.
Market Data 
Markets 
